SAN FRANCISCO, May 2, 2024 /PRNewswire/ — MedGenome, a global partner for comprehensive multiomics solutions, in collaboration with PacBio, is pleased to announce Dr. Lauren Esposito of the California Academy of Sciences as the recipient of the ‘2024 de novo genome assembly and annotation grant‘. Dr. Lauren Esposito, Curator and Schlinger Chair of Arachnology at […]
FOSTER CITY, Calif., Nov. 28, 2023 /PRNewswire/ — MedGenome, a global precision medicine company specializing in omics solutions today announced the appointment of Martin Dewhurst, a McKinsey veteran for over 30 years as the Chairman of its Advisory Board. Martin’s wealth of expertise and extensive experience in the life sciences space will play a key
FOSTER CITY, Calif., Nov. 21, 2023 /PRNewswire/ — MedGenome, a global partner for comprehensive multiomics solutions, is pleased to announce a grant for De Novo Genome Assembly and Annotation, in collaboration with PacBio, a pioneer in long-read sequencing. The winner will be selected by a panel of experts from MedGenome and PacBio. The grant awardee
FOSTER CITY, Calif., Nov. 7, 2023 /PRNewswire/ — MedGenome, a global precision medicine company specializing in omics solutions, announced today that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering. This certification further illustrates MedGenome’s commitment to delivering fast, high-quality insights at single cell level to help solve the
FOSTER CITY, Calif.–(BUSINESS WIRE)–MedGenome, a global precision medicine company specializing in omics solutions, today announced that it will be exhibiting at the American Association for Cancer Research Annual Meeting on April 14 – 19, 2023 in Orlando, Florida. MedGenome will be at Booth #2074 to exhibit its advanced single cell sequencing and immune repertoire profiling
FOSTER CITY, Calif., Aug. 24, 2020 /PRNewswire/ — In a paper published in Nature Communications, scientists from MedGenome India/USA, along with an international team of scientists from institutions in India, USA, South Korea, Chile and Australia reported sequencing and analysis of over 150 gallbladder cancer (GBC) samples. Currently, there are no targeted therapies for treating
FOSTER CITY, California, April 1, 2020 /PRNewswire/ — MedGenome, the leading genetic diagnostics, research and data company focused on expanding access for populations in South Asia and other emerging markets today announced an investment of USD 55m led by LeapFrog Investments, a leading specialist investor in emerging markets. Existing investors Sofina and Sequoia also participated
FOSTER CITY, California, Nov. 18, 2019 /PRNewswire/ — MedGenome, a global leader in personalized medicine, announced the development of a proprietary genotyping array to efficiently enable large-scale genetic studies focused on South Asian populations. The South Asian Research Genotyping Array by MedGenome (“SARGAM”) will be optimized for capturing the unique variants found in South Asian
FOSTER CITY, CALIFORNIA, UNITED STATES, October 29, 2018 /EINPresswire.com/ — Scientists from MedGenome, Bangalore, India in collaboration with oncologists from Tata Memorial Hospital, Mumbai, India and scientists at Genentech, a member of the Roche Group, South San Francisco, Calif., USA, report in Cancer Cell the identification of a treatable mutation linked to lung cancer. A
MedGenome’s recent paper “A cancer vaccine approach for personalized treatment of Lynch Syndrome” is published in Scientific Reports FOSTER CITY, CALIFORNIA, UNITED STATES, August 21, 2018 /EINPresswire.com/ — The published study examines the feasibility of treating Lynch syndrome using a personalized cancer vaccine approach by identifying potential immunogenic tumor specific alterations. Lynch syndrome is a
